Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $26 from $22 and maintained a Sector Perform rating on the shares. The rating update came after the company reported its fiscal Q4 financial results, with the firm telling investors that Beam Therapeutics Inc. (NASDAQ:BEAM) is continually targeting BLA submission this year on sickle cell disease, and anno ...